Oliveira Carla, Pinto Mafalda, Duval Alex, Brennetot Caroline, Domingo Enric, Espín Eloi, Armengol Manel, Yamamoto Hiroyuki, Hamelin Richard, Seruca Raquel, Schwartz Simó
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Porto 4200-465, Portugal.
Oncogene. 2003 Dec 11;22(57):9192-6. doi: 10.1038/sj.onc.1207061.
Genes from the RAF family are Ras-regulated kinases involved in growth cellular responses. Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorectal tumors and significantly associated to defective mismatch repair (MMR). Additionally, BRAF mutations were described only in K-Ras-negative colon carcinomas, suggesting that BRAF/K-Ras activating mutations might be alternative genetic events in colon cancer. We have addressed to what extent the tumorigenic-positive selection exerted by BRAF mutations seen in colorectal MMR-deficient tumors was also involved in the tumorigenesis of gastric cancer. Accordingly, BRAF mutations were detected in 34% (25/74) of colorectal MMR-deficient tumors and in 5% (7/142) of MMR-proficient colorectal cases (P=0.0001). All mutations found in the MSI cases corresponded to the previously reported hotspot V599E. Two D593K and a K600E additional mutations were also detected in three MSS cases. However, only one mutation of BRAF was found within 124 MSS gastric tumors and none in 37 MSI gastric tumors, clearly suggesting that BRAF mutations are not involved in gastric tumorigenesis. Nonetheless, a high incidence of mutations of K-Ras was found within the MSI gastric group of tumors (P=0.0005), suggesting that the activation of K-Ras-dependent pathways contributes to the tumorigenesis of gastric cancers with MMR deficiency. Accordingly, our results show evidences that BRAF mutations characterize colon but not gastric tumors with MMR deficiency and are not involved in the tumorigenesis of gastric cancer of the mutator phenotype pathway.
RAF家族基因是参与细胞生长反应的Ras调节激酶。最近,在高比例的结直肠癌中报道了BRAF基因内的V599E热点突变,且该突变与错配修复缺陷(MMR)显著相关。此外,BRAF突变仅在K-Ras阴性结肠癌中被描述,这表明BRAF/K-Ras激活突变可能是结肠癌中的替代遗传事件。我们研究了在结直肠癌MMR缺陷肿瘤中所见的BRAF突变所施加的致瘤性正向选择在多大程度上也参与了胃癌的肿瘤发生。相应地,在34%(25/74)的结直肠癌MMR缺陷肿瘤和5%(7/142)的MMR功能正常的结直肠癌病例中检测到BRAF突变(P = 0.0001)。在微卫星高度不稳定(MSI)病例中发现的所有突变均对应于先前报道的热点V599E。在三例微卫星稳定(MSS)病例中还检测到两个D593K和一个K600E额外突变。然而,在124例MSS胃癌肿瘤中仅发现1例BRAF突变,在37例MSI胃癌肿瘤中未发现BRAF突变,这清楚地表明BRAF突变不参与胃癌的肿瘤发生。尽管如此,在MSI胃癌肿瘤组中发现K-Ras突变的发生率很高(P = 0.0005),这表明K-Ras依赖途径的激活有助于MMR缺陷型胃癌的肿瘤发生。因此,我们的结果表明,BRAF突变是MMR缺陷型结肠癌而非胃癌的特征,且不参与错配修复缺陷型胃癌的肿瘤发生。